ASIT biotech strongly reduces the size of its organization and re-focus on developing treatments for food allergies, following the results of the Phase III trial of its gp-ASIT+TM treatment in grass pollen allergy. Real-life exposure trials required for respiratory programs such as gp-ASIT+TM represent inherent challenges that are difficult to overcome even for big pharma. In the recent Phase III trial (ABT-gpASIT011), gp-ASIT+TM showed a 0.15 (p=0.05) absolute reduction in the Combined Symptom and Medication Score (CSMS) during the peak of the grass pollen (GP) season, and a 0.18 (p=0.005) absolute reduction in the CSMS during the entire GP season, versus the primary endpoint of 0.30. Both groups took an extensive amount of other medication against allergic symptoms during the study period, which potentially masked the efficacy of gp-ASIT+TM, and despite this the data show a statistically significant treatment effect over placebo, consistent with the previous Phase III trial (BTT009). Moreover, blood analysis of immunological parameters has confirmed an immune response in gp-ASIT+TM patients, in line with the mechanistic study published in the Journal of Allergy and Clinical Immunology earlier this year, but the persistence of the effect was not long enough, potentially questioning gp-ASIT+TM dosing. Based on the extensive pre-clinical and clinical data sets across all of its programs, ASIT biotech firmly believes its technological platform can be adapted to any protein-based allergen, and that there is extensive value in further developing a pipeline against food allergens where the unmet need is the highest. In order to minimize cash expenses to identify new options and to reach new objectives, the Board of Directors has also decided to reduce the organization to the strict minimum and has filed a request for judicial reorganization. As a consequence, the gp-ASIT+TM program is placed on hold pending further discussions.